VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Participants must have English fluency sufficient  │ Participants must have English fluency sufficient  │     100 │
│ to complete study measures                         │ to complete study measures                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in other interventional research     │ Participation in other interventional research     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of penetrating head injury                 │ History of penetrating head injury                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of TBI more severe than mild by DVBIC      │ History of TBI more severe than mild by DVBIC      │     100 │
│ criteria                                           │ criteria                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of prazosin or other alpha-1 antagonist        │ Use of prazosin or other alpha-1 antagonist        │     100 │
│ (including but not limited to alfuzosin,           │ (including but not limited to alfuzosin,           │         │
│ doxazosin, silodosin, tamsulosin, terazosin) for   │ doxazosin, silodosin, tamsulosin, terazosin) for   │         │
│ any purpose in the 2 weeks prior to initial screen │ any purpose in the 2 weeks prior to initial screen │         │
│ (P1) visit and prohibited throughout the study     │ (P1) visit and prohibited throughout the study     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Allergy or previous adverse reaction to prazosin   │ Allergy or previous adverse reaction to prazosin   │     100 │
│ or other alpha-1 antagonist                        │ or other alpha-1 antagonist                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active psychosis or psychotic disorder, severe     │ Active psychosis or psychotic disorder, severe     │     100 │
│ depression (as determined per clinician prescriber │ depression (as determined per clinician prescriber │         │
│ judgment), severe psychiatric instability or       │ judgment), severe psychiatric instability or       │         │
│ severe situational life crisis (including evidence │ severe situational life crisis (including evidence │         │
│ of being actively suicidal or homicidal)           │ of being actively suicidal or homicidal)           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Meets Diagnostic and Statistical Manual of Mental  │ Meets Diagnostic and Statistical Manual of Mental  │     100 │
│ Disorders, 5th Edition (DSM-5) criteria for any    │ Disorders, 5th Edition (DSM-5) criteria for any    │         │
│ Substance Use Disorder except caffeine-related     │ Substance Use Disorder except caffeine-related     │         │
│ disorders, or tobacco-related disorders            │ disorders, or tobacco-related disorders            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of delirium within the prior 3 months,     │ History of delirium within the prior 3 months,     │     100 │
│ epilepsy, stroke, dementia, psychotic disorder, or │ epilepsy, stroke, dementia, psychotic disorder, or │         │
│ bipolar disorder                                   │ bipolar disorder                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Structural brain abnormalities on any prior        │ Structural brain abnormalities on any prior        │     100 │
│ imaging with associated clinically evident         │ imaging with associated clinically evident         │         │
│ manifestations                                     │ manifestations                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current participation in transcranial magnetic     │ Current participation in transcranial magnetic     │     100 │
│ stimulation studies                                │ stimulation studies                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of childbearing potential must not be        │ Women of childbearing potential must not be        │     100 │
│ pregnant, planning to become pregnant during the   │ pregnant, planning to become pregnant during the   │         │
│ study period, or nursing                           │ study period, or nursing                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in a HA support group or other       │ Participation in a HA support group or other       │     100 │
│ activity such as meditation or yoga intended to    │ activity such as meditation or yoga intended to    │         │
│ mitigate HA or other chronic pain must be stable   │ mitigate HA or other chronic pain must be stable   │         │
│ at least 4 weeks prior to beginning the initial    │ at least 4 weeks prior to beginning the initial    │         │
│ screen (P1) visit and may not be started during    │ screen (P1) visit and may not be started during    │         │
│ the study                                          │ the study                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Failure to record HA data for at least 80% of days │ Failure to record HA data for at least 80% of days │     100 │
│ during the Screening Period                        │ during the Screening Period                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Not suitable for study per clinician judgement     │ Not suitable for study per clinician judgement     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Opioid Medications: Use of opioids for treatment   │ Opioid Medications: Use of opioids for treatment   │     100 │
│ of HA or non-HA-related pain or for any other      │ of HA or non-HA-related pain or for any other      │         │
│ purpose is allowed during the study. Any opioid    │ purpose is allowed during the study. Any opioid    │         │
│ use would ideally be excluded due to potential     │ use would ideally be excluded due to potential     │         │
│ confounding effects on interpretation of response  │ confounding effects on interpretation of response  │         │
│ to treatment. However, in this population,         │ to treatment. However, in this population,         │         │
│ particularly in Veterans with chronic pain or      │ particularly in Veterans with chronic pain or      │         │
│ undergoing minor orthopedic or dental procedures,  │ undergoing minor orthopedic or dental procedures,  │         │
│ opioid use is common. Use of opioids, including    │ opioid use is common. Use of opioids, including    │         │
│ frequency and dose, will be recorded on the        │ frequency and dose, will be recorded on the        │         │
│ concurrent medication CRF                          │ concurrent medication CRF                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Psychoactive drugs (for example, anticonvulsants,  │ Psychoactive drugs (for example, anticonvulsants,  │     100 │
│ benzodiazepines, antidepressants,                  │ benzodiazepines, antidepressants,                  │         │
│ sedative/hypnotics)                                │ sedative/hypnotics)                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hormones (for example, testosterone, estrogen, or  │ Hormones (for example, testosterone, estrogen, or  │     100 │
│ progesterone) in any form                          │ progesterone) in any form                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The use of butalbital in any form within 4 weeks   │ The use of butalbital in any form within 4 weeks   │     100 │
│ of beginning the Preliminary Screening Period (P1) │ of beginning the Preliminary Screening Period (P1) │         │
│ through the end of the participant's study         │ through the end of the participant's study         │         │
│ involvement is exclusionary                        │ involvement is exclusionary                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants who have been taking trazodone will   │ Participants who have been taking trazodone will   │     100 │
│ undergo a 2-week washout period before the         │ undergo a 2-week washout period before the         │         │
│ Preliminary Screening Period (P1 visit). Combining │ Preliminary Screening Period (P1 visit). Combining │         │
│ prazosin and trazodone may increase the risk of    │ prazosin and trazodone may increase the risk of    │         │
│ priapism. We have decided to begin the washout     │ priapism. We have decided to begin the washout     │         │
│ period before the Preliminary Screening Period in  │ period before the Preliminary Screening Period in  │         │
│ order to remove any confounding variables while on │ order to remove any confounding variables while on │         │
│ the headache log and actigraphy                    │ the headache log and actigraphy                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Sildenafil (Viagra), tadalafil (Cialis),           │ Sildenafil (Viagra), tadalafil (Cialis),           │     100 │
│ vardenafil (Levitra), and avanafil (Stendra) will  │ vardenafil (Levitra), and avanafil (Stendra) will  │         │
│ not be permitted during the study drug dose        │ not be permitted during the study drug dose        │         │
│ Titration Period, because of increased risk of     │ Titration Period, because of increased risk of     │         │
│ hypotension in combination with alpha-1 blockers,  │ hypotension in combination with alpha-1 blockers,  │         │
│ but will be allowed at half the usual starting     │ but will be allowed at half the usual starting     │         │
│ dose following the study drug dose Titration       │ dose following the study drug dose Titration       │         │
│ Period, per VA prescribing guidelines              │ Period, per VA prescribing guidelines              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of supplements containing nitrates and         │ Use of supplements containing nitrates and         │     100 │
│ supplements containing stimulants (such as         │ supplements containing stimulants (such as         │         │
│ ephedra) are exclusionary in the two weeks prior   │ ephedra) are exclusionary in the two weeks prior   │         │
│ to initial screen (P1) visit and prohibited        │ to initial screen (P1) visit and prohibited        │         │
│ throughout the study. Participants who take these  │ throughout the study. Participants who take these  │         │
│ supplements will be asked to discontinue them for  │ supplements will be asked to discontinue them for  │         │
│ a minimum of two weeks before the Preliminary      │ a minimum of two weeks before the Preliminary      │         │
│ Screening Period (P1 visit)                        │ Screening Period (P1 visit)                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of prescribed stimulants (such as amphetamine  │ Use of prescribed stimulants (such as amphetamine  │     100 │
│ or dextroamphetamine containing medications) is    │ or dextroamphetamine containing medications) is    │         │
│ exclusionary in the 2 weeks prior to the initial   │ exclusionary in the 2 weeks prior to the initial   │         │
│ screen (P1) visit and prohibited throughout the    │ screen (P1) visit and prohibited throughout the    │         │
│ study. Participants who take these medications     │ study. Participants who take these medications     │         │
│ will be asked to discontinue them for a minimum of │ will be asked to discontinue them for a minimum of │         │
│ 2 weeks before the Preliminary Screening Period    │ 2 weeks before the Preliminary Screening Period    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ o Mild TBI is defined as an injury to the head     │ History of blast and/or impact head trauma mTBI    │      85 │
│ causing at least one of the following: alteration  │ meeting Defense and Veterans Brain Injury Center   │         │
│ in consciousness (for up to 24 hours after the     │ (DVBIC) mTBI criteria, which define mTBI as an     │         │
│ injury), loss of consciousness (0-30 minutes),     │ injury to the head causing at least one of the     │         │
│ and/or post-traumatic amnesia (up to 1 day post-   │ following: alteration in consciousness (for up to  │         │
│ injury). If available, the Glasgow Coma Scale      │ 24 hours after the injury), loss of consciousness  │         │
│ score must be 13-15, and head imaging findings (if │ 0-30 minutes, and/or post-traumatic amnesia up to  │         │
│ imaging was performed) must be negative            │ 1 day post-injury. If available, the Glasgow Coma  │         │
│                                                    │ Scale score must be 13-15, and head imaging        │         │
│                                                    │ findings (if imaging was performed) must be        │         │
│                                                    │ negative                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants of childbearing potential must agree  │ Women of childbearing potential must agree to      │      90 │
│ to abstain from sexual relations that could result │ abstain from sexual relations that could result in │         │
│ in pregnancy or use an effective method of birth   │ pregnancy or use an effective method of birth      │         │
│ control acceptable to both participant and the     │ control acceptable to both participant and the     │         │
│ clinician prescriber during the study.             │ clinician prescriber during the study. Men are not │         │
│ Participants who are not of childbearing potential │ required to use contraception during the study     │         │
│ are not required to use contraception during the   │                                                    │         │
│ study                                              │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute or serious medical illness or unstable       │ Acute or serious medical illness or unstable       │      90 │
│ chronic medical illness (e.g., unstable angina,    │ chronic medical illness (e.g., unstable angina,    │         │
│ myocardial infarction within 6 months, congestive  │ myocardial infarction within 6 months, congestive  │         │
│ heart failure, clinically significant or           │ heart failure, clinically significant or           │         │
│ concerning cardiac arrhythmias; preexisting        │ concerning cardiac arrhythmias; preexisting        │         │
│ hypotension \[systolic blood pressure\<110\] or    │ hypotension [systolic blood pressure<110] or       │         │
│ orthostatic hypotension \[systolic drop \>20 mm Hg │ orthostatic hypotension [systolic drop >20 mm Hg   │         │
│ after 2 min standing accompanied by                │ after 2 min standing accompanied by                │         │
│ lightheadedness\], chronic renal or hepatic        │ lightheadedness], chronic renal or hepatic         │         │
│ failure, or acute pancreatitis. The eligibility of │ failure, acute pancreatitis, Meniere's disease, or │         │
│ potential participants having acute serious and/or │ diagnosed but untreated sleep apnea). The          │         │
│ chronic medical illnesses other than those listed  │ eligibility of potential participants having acute │         │
│ will be evaluated on a case-by-case basis by a     │ serious and/or chronic medical illnesses other     │         │
│ study physician, physician assistant - certified   │ than those listed will be evaluated on a case-by-  │         │
│ (PA-C), or advanced registered nurse practitioner  │ case basis by a study physician, PA-C, or ARNP     │         │
│ (ARNP)                                             │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male and female Active-duty Servicemembers (SMs)   │ Male and female Active-duty SMs or Veterans aged   │      91 │
│ or Veterans aged 18 or older who are in good       │ 18 or older who are in good general health         │         │
│ general health                                     │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The use of magnesium in any dose that is           │ The use of magnesium in any dose that is           │      92 │
│ prescribed for the purpose of HA prevention or     │ prescribed for the purpose of HA prevention or     │         │
│ treatment. The incidental use of magnesium in      │ treatment must be stable for at least 4 weeks. The │         │
│ multi-vitamins, laxatives, etc. is permissible but │ incidental use of magnesium in multi-vitamins,     │         │
│ must be documented                                 │ laxatives, etc. is permissible but must be         │         │
│                                                    │ documented                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The use of HA rescue or symptom-relieving          │ The use of HA rescue or symptom-relieving          │      93 │
│ medications will be allowed during the study. This │ medications will be allowed during the study. This │         │
│ includes triptans, ergotamines, opioids, simple    │ includes triptans, ergotamines, opioids, simple    │         │
│ analgesics (e.g. acetaminophen, aspirin, or non-   │ analgesics (e.g. acetaminophen, aspirin, or non-   │         │
│ steroidal anti-inflammatories \[NSAIDS\], and      │ steroidal anti-inflammatories [NSAIDS], and        │         │
│ combination analgesics. Their use will be recorded │ combination analgesics. Their use will be recorded │         │
│ on the concurrent medication case report form      │ on the concurrent medication CRF during the        │         │
│ (CRF) during the Preliminary Screening Period (P1) │ Preliminary Screening Period (P1) and throughout   │         │
│ and throughout the remainder of the study.         │ the remainder of the study. Randomization of       │         │
│ Randomization of participants will be stratified   │ participants will be stratified based on whether   │         │
│ based on whether their use of HA medications meets │ their use of HA medications meets ICHD-3 beta      │         │
│ International Classification of Headache Disorders │ criteria for overuse of these medications, as      │         │
│ 3rd addition (ICHD-3 beta) criteria for overuse of │ described in section 5.5 below                     │         │
│ these medications, as described in section 5.5     │                                                    │         │
│ below                                              │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other Medications: Participants who are using      │ Other Medications: Participants who are taking     │      96 │
│ other medications or treatments on a routine basis │ other medications on a routine basis must be on a  │         │
│ must be on a stable dose for at least 4 weeks      │ stable dose for at least 4 weeks prior to the      │         │
│ prior to the Preliminary Screening Period (P1),    │ Preliminary Screening Period (P1), and must intend │         │
│ and must intend to continue the medication at the  │ to continue the medication at the same regimen for │         │
│ same regimen for the duration of the trial unless  │ the duration of the trial unless lack of efficacy, │         │
│ lack of efficacy, safety, or tolerability dictates │ safety, or tolerability dictates otherwise. The    │         │
│ otherwise. The following medications and           │ following medications are not excluded             │         │
│ treatments are not excluded                        │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HAs of any kind of moderate or severe intensity on │ HAs of any kind of moderate or severe intensity on │      99 │
│ an average of more than 4 days per month preceding │ an average of more than 2 days per month preceding │         │
│ the concussive trauma                              │ the concussive trauma                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Antihypertensive medications (including beta-      │ Antihypertensive medications (including beta-      │      99 │
│ blockers, calcium channel blockers, angiotensin    │ blockers, calcium channel blockers, angiotensin    │         │
│ converting enzyme \[ACE\] inhibitors, and          │ converting enzyme [ACE] inhibitors, and            │         │
│ angiotensin receptor blockers)                     │ angiotensin receptor blockers)                     │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                  │ Participants must have English fluency sufficient  │      40 │
│                                                    │ to complete study measures                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Frequent headaches (HAs) that started within 3     │ HAs of any kind of moderate or severe intensity on │      41 │
│ months after a head injury or marked worsening (a  │ an average of more than 2 days per month preceding │         │
│ two-fold or greater increase in frequency and/or   │ the concussive trauma                              │         │
│ severity) of pre-existing headaches within 3       │                                                    │         │
│ months of head injury                              │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of blast and/or impact head trauma mild    │ History of TBI more severe than mild by DVBIC      │      44 │
│ traumatic brain injury (mTBI) meeting Defense and  │ criteria                                           │         │
│ Veterans Brain Injury Center (DVBIC) mTBI criteria │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A primary non migraine and/or tension-type HA      │ HAs of any kind of moderate or severe intensity on │      44 │
│ disorder (for example hemicrania continua;         │ an average of more than 2 days per month preceding │         │
│ cluster) that accounts for the majority of current │ the concussive trauma                              │         │
│ symptoms                                           │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cannabis: The use of cannabis in any form is not   │ The use of magnesium in any dose that is           │      48 │
│ excluded unless its use meets criteria for         │ prescribed for the purpose of HA prevention or     │         │
│ Cannabis Use Disorder. All use of cannabis will be │ treatment must be stable for at least 4 weeks. The │         │
│ documented                                         │ incidental use of magnesium in multi-vitamins,     │         │
│                                                    │ laxatives, etc. is permissible but must be         │         │
│                                                    │ documented                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Onabotulinum toxin A and nerve block injections    │ The use of magnesium in any dose that is           │      49 │
│ for the purpose of HA prevention are permissible   │ prescribed for the purpose of HA prevention or     │         │
│ if the treatment response has been stable during   │ treatment must be stable for at least 4 weeks. The │         │
│ the two most recent treatment cycles               │ incidental use of magnesium in multi-vitamins,     │         │
│                                                    │ laxatives, etc. is permissible but must be         │         │
│                                                    │ documented                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medication-and other Treatment-Related             │ Participation in other interventional research     │      51 │
│ Considerations                                     │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HAs either 1) must last 4 or more hours a day and  │ Frequent HAs that started within 3months after a   │      57 │
│ reach a moderate to severe intensity at any point  │ head injury. The HAs either 1) must last 4 or more │         │
│ during the headache, or 2) may be of any severity  │ hours a day and reach a moderate to severe         │         │
│ or duration if the participant takes a medication  │ intensity at any point during the headache, or 2)  │         │
│ or other agent in an effort to stop or treat a     │ may be of any severity or duration if the          │         │
│ headache                                           │ participant takes a triptan or ergotamine. HAs     │         │
│                                                    │ meeting these criteria must have been present on   │         │
│                                                    │ average at least 8 days per 4-week period,         │         │
│                                                    │ starting within 30 days after head injury and      │         │
│                                                    │ occurring by self-report for at least 3 months     │         │
│                                                    │ prior to the Initial Screening Visit. The 4-week   │         │
│                                                    │ HA frequency/severity criteria must be confirmed   │         │
│                                                    │ during the Preliminary Screening Period            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HAs meeting these criteria must have been present  │ Frequent HAs that started within 3months after a   │      63 │
│ on average at least 8 days per 4-week period and   │ head injury. The HAs either 1) must last 4 or more │         │
│ occurring at a stable level by self-report for at  │ hours a day and reach a moderate to severe         │         │
│ least 3 months prior to the Initial Screening      │ intensity at any point during the headache, or 2)  │         │
│ Visit. The 4-week HA frequency/severity criteria   │ may be of any severity or duration if the          │         │
│ must be confirmed during the Preliminary Screening │ participant takes a triptan or ergotamine. HAs     │         │
│ Period                                             │ meeting these criteria must have been present on   │         │
│                                                    │ average at least 8 days per 4-week period,         │         │
│                                                    │ starting within 30 days after head injury and      │         │
│                                                    │ occurring by self-report for at least 3 months     │         │
│                                                    │ prior to the Initial Screening Visit. The 4-week   │         │
│                                                    │ HA frequency/severity criteria must be confirmed   │         │
│                                                    │ during the Preliminary Screening Period            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The "as-needed" (prn) use of any non-exclusionary  │ The "as-needed" (prn) use of psychoactive and      │      80 │
│ medications is allowed; however, such use must be  │ other drugs such as antibiotics is not excluded;   │         │
│ discussed with a clinician prescriber and          │ however, such use must be discussed with a         │         │
│ documented                                         │ clinician prescriber and documented                │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ History of penetrating head injury                 │ Lifetime history of 5 or more migraine or probable │      42 │
│                                                    │ migraine headaches pre-dating mTBI                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Allergy or previous adverse reaction to prazosin   │ Diagnosis of a primary or secondary HA disorder    │      43 │
│ or other alpha-1 antagonist                        │ other than PTHA                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HAs of any kind of moderate or severe intensity on │ Continuous HAs of any kind (i.e., persistent daily │      46 │
│ an average of more than 4 days per month preceding │ HAs with no HA-free period less than 8 hours       │         │
│ the concussive trauma                              │ between attacks)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HAs meeting these criteria must have been present  │ Frequent HAs that started within 3months after a   │      63 │
│ on average at least 8 days per 4-week period and   │ head injury. The HAs either 1) must last 4 or more │         │
│ occurring at a stable level by self-report for at  │ hours a day and reach a moderate to severe         │         │
│ least 3 months prior to the Initial Screening      │ intensity at any point during the headache, or 2)  │         │
│ Visit. The 4-week HA frequency/severity criteria   │ may be of any severity or duration if the          │         │
│ must be confirmed during the Preliminary Screening │ participant takes a triptan or ergotamine. HAs     │         │
│ Period                                             │ meeting these criteria must have been present on   │         │
│                                                    │ average at least 8 days per 4-week period,         │         │
│                                                    │ starting within 30 days after head injury and      │         │
│                                                    │ occurring by self-report for at least 3 months     │         │
│                                                    │ prior to the Initial Screening Visit. The 4-week   │         │
│                                                    │ HA frequency/severity criteria must be confirmed   │         │
│                                                    │ during the Preliminary Screening Period            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The "as-needed" (prn) use of any non-exclusionary  │ The "as-needed" (prn) use of psychoactive and      │      80 │
│ medications is allowed; however, such use must be  │ other drugs such as antibiotics is not excluded;   │         │
│ discussed with a clinician prescriber and          │ however, such use must be discussed with a         │         │
│ documented                                         │ clinician prescriber and documented                │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 91
Average Levenshtein Ratio of individual lines: 83.53191489361703
OverAll Ratio: 87.26595744680851
